Todd Shriber

Todd Shriber

InvestorPlace Contributor

Recent Articles

Dow Jones Today: Easing Coronavirus Concerns Propel Stocks Higher

By Todd Shriber, InvestorPlace Contributor

UnitedHealth was an epic winner for the Dow Jones today, but that big pop requires more examination. Here's why.

Apple Stock Won’t Move up in a Straight Line, but It’s Still a Buy

By Todd Shriber, InvestorPlace Contributor

For fans of such anecdotes, a $100 investment in Apple in 2010 was worth more than $1,100 at the end of 2019. That's obviously a stellar return, but it should not imply that Apple is done delivering for investors. Yes, there will be bumps along the way and asking Apple to be worth $2.8 trillion at this time next year is asking a lot, but betting against Tim Cook and team is a risky proposition at best.

Dow Jones Today: China-Sensitive Names Lead the Way

By Todd Shriber, InvestorPlace Contributor

Gains were modest as tech stocks were pinched by news that the FTC is planning to review old deals by Apple, Microsoft and others.

There’s No Miraculous Comeback Looming for Acasti Pharma Stock

By Todd Shriber, InvestorPlace Contributor

Acasti's Phase 3 trial of CaPre, aimed at patients with high levels of triglycerides, isn't working out, explaining why the stock is down 69.11% to start 2020. One of the primary causes of concern with the Trilogy 1 Phase 3 trial of CaPre was that there were unanticipated levels of placebo response. Said another way, patients got a cornstarch pill, which of course would be far less expensive than any drug, and had a positive reaction to it.

Dow Jones Today: Stocks Shrug Off Q1 GDP Warning

By Todd Shriber, InvestorPlace Contributor

Stocks pushed higher again today with broad-based contributions, even though a tepid first-quarter GDP estimate was published this morning.

Load More